A Comparative Study between Olanzapine and Risperidone in the Management of Schizophrenia
Table 3
Between-group analysis of different outcome measures at weeks 4, 8, and 12.
Measures
Olanzapine
Risperidone
95% CI
SAPS-4th week
61.44 ± 3.92
61.23 ± 3.61
0.216
0.82
−1.74, 2.16
SAPS-8th week
60.27 ± 3.82
60.98 ± 3.58
−0.743
0.46
−2.62, 1.20
SAPS-12th week
54.96 ± 3.42
56.31 ± 3.02
−1.621
0.11
−3.02, 0.32
SANS-4th week
45.19 ± 2.73
45.69 ± 2.29
−0.769
0.44
−1.80, 0.80
SANS-8th week
44.91 ± 3.37
45.76 ± 3.33
−0.983
0.32
−2.58, 0.88
SANS-12th week
42.74 ± 3.69
45.28 ± 3.06
−2.902
0.005
−4.29, −0.79
SAI-12th week
3.83 ± 0.11
3.97 ± 0.74
−1.025
0.30
−0.41, 0.13
SAS-12th week
0.38 ± 0.02
0.45 ± 0.19
−2.007
0.04
−0.14, −0.00
CGI-S-12th week
3.10 ± 1.03
3.17 ± 0.16
−0.368
0.71
−0.45, 0.31
SAPS: Scale for Assessment of Positive Symptoms; SANS: Scale for Assessment of Negative Symptoms; CGI-S: Clinical Global Impressions-Severity Scale; SAI: Schedule for Assessment of Insight; SAS: Simpson Angus Scale.
